MedTrace Logo

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

NCT03829449 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-04-10

Study results available
· View outcomes & findings →

Summary

Long term management of patients with complement related diseases including Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome

Conditions

Interventions

DRUG

rVA576

The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).

Sponsors & Collaborators

  • AKARI Therapeutics

    lead INDUSTRY

Principal Investigators

  • Wynne Weston Davies · AKARI Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2020-08-29
Completion
2020-08-29
FDA Drug
Yes

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03829449 on ClinicalTrials.gov